Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
BPC-157 ulcerative colitis: what the research says BPC-157 is a small peptide first described in gastric juice
In one study of perceptions of long-acting injections (LAIs) compared to pills, for example, the perceived advantage for LAI over pills and the belief about the better efficiency of LAI were the main factors that drove the preference for LAI
Composition BPC-157: 10 mg TB-500 (Thymosin Beta 4): 10 mg Appearance: lyophilized powder in a sealed research vial Research Focus (non-clinical) Combined evaluation of BPC-157 and TB-500 in in-vitro or ex-vivo assay systems Assay development, including chromatographic separation of two co-formulated peptides Stability characterization of a two-analyte lyophilized blend under laboratory storage conditions Documentation Lot-specific COA Batch and lot traceability Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA Lyophilized for transit stability
What side effects can happen with lipotropic injections
US$ 24.07
US$ 25.49
US$ 28.83
US$ 27.18
US$ 21.57
